Key result
Endocardial catheter ablation successfully treats drug-resistant monomorphic VT in a child with Brugada syndrome.
Why the study?
Epicardial ablation of RVOT arrhythmias is reported in adults with drug-resistant Brugada syndrome, but an epicardial approach is uncommon in pediatric patients where endocardial ablation is often initially attempted.
Case Report (n=1)
Endocardial catheter ablation can be a successful treatment for drug-resistant monomorphic ventricular tachycardia in pediatric patients with Brugada syndrome.
May support endocardial ablation for refractory VT in pediatric Brugada syndrome; extends sparse case data but leaves open need for prospective studies.
Brugada syndrome (BrS) is an inherited arrhythmia that may cause fatal ventricular tachyarrhythmias in mainly males between their fourth and fifth decade of life.1 Recently, epicardial radiofrequency (RF) ablation of right ventricular outflow tract (RVOT) arrhythmias has been performed to eliminate the arrhythmogenic substrate in cases not responding to first-line medications such as bepridil, and a favorable outcome has been reported in adults.2 In pediatric patients, however, an epicardial approach is still uncommon and endocardial ablation is often initially attempted.
No takes yet. Share an insight, caveat, or question.
Nabeshima et al. (2020) conducted a case report in Brugada syndrome with drug-resistant monomorphic ventricular tachycardia (n=1). Endocardial catheter ablation was evaluated on Successful ablation of ventricular tachycardia. Endocardial catheter ablation successfully treated drug-resistant monomorphic ventricular tachycardia in a child with Brugada syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: